Cinctive Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Cinctive Capital Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-23,317	Closed	-$1.05M	–	530
2025 Q4	$1.05M	Buy	23,317 +263	+1%	+$11K	0.06%	280
2025 Q3	$926K	Buy	+23,054	New	+$812K	0.04%	309
2024 Q3	–	Sell	-20,520	Closed	-$800K	–	536
2024 Q2	$800K	Sell	20,520 -11,250	-35%	-$450K	0.04%	325
2024 Q1	$1.37M	Buy	31,770 +4,170	+15%	+$192K	0.06%	255
2023 Q4	$1.27M	Buy	+27,600	New	+$975K	0.08%	229
2022 Q3	–	Sell	-41,073	Closed	-$1.25M	–	636
2022 Q2	$1.25M	Sell	41,073 -1,230	-3%	-$37.2K	0.05%	367
2022 Q1	$1.29M	Hold	42,303	–	–	0.05%	376
2021 Q4	$1.32M	Buy	+42,303	New	+$1.26M	0.06%	363

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Cinctive Capital Management's XENE Position: Q1 2026 in Review

Cinctive Capital Management sold out of Xenon Pharmaceuticals (XENE) in Q1 2026, closing a stake of 23,317 shares — an estimated $1.05M sold.

Cinctive Capital Management first reported a position in XENE in Q4 2021 and held it in 8 quarters. The position peaked at $1.37M in Q1 2024. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

Cinctive Capital Management reported no remaining Xenon Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Cinctive Capital Management sold 23,317 Xenon Pharmaceuticals shares in Q1 2026, an estimated $1.05M.
Cinctive Capital Management first reported a position in Xenon Pharmaceuticals in Q4 2021 and held it in 8 quarters.
Cinctive Capital Management's Xenon Pharmaceuticals position peaked at $1.37M in Q1 2024.
290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Cinctive Capital Management's 13F filing for Q1 2026, filed 15 May 2026.